Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5→16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Persistent Losses • Equity Dilution TNGX has ample liquidity but remains cash-burning, unprofitable, diluted, and difficult to justify on current valuation metrics.
Price Behavior
Key Price Behavior Insights: • Monthly downtrend • Support defended • Resistance overhead Support Level: $22.30–$22.70 Resistance Level: $24.00–$24.50 TNGX remains technically bearish over the last month, with support at $22.30–$22.70 and a sustained break above $24.50 needed to improve momentum.
Sentiment & News
Key News Insights: • Post-Earnings Decline • Mixed Institutional Activity • Pipeline Data Ahead Tango Therapeutics shares fell 6.2% post-earnings amid mixed institutional trading, with upcoming clinical data and Phase 3 plans remaining key catalysts.
AI Summary
TNGX is now a high-upside, concentrated clinical bet on whether vopimetostat plus daraxonrasib can reproduce its 92% response rate in larger, durable pancreatic-cancer datasets; its $1.0B cash balance removes near-term funding pressure, but failure to validate the early result or secure a workable regulatory path would sharply reset valuation.
Description
Tango Therapeutics is a Cambridge, Massachusetts–based biotechnology company that discovers and develops small-molecule therapies for cancer. Its lead candidate, TNG908, is a PRMT5 inhibitor targeting tumors with MTAP deletions, and the pipeline includes inhibitors directed at USP1 for BRCA1/2-mutant cancers and a program for STK11-mutant tumors. The company maintains a strategic discovery and development collaboration with Gilead Sciences and was founded in 2017.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | TNGX | Tango Therapeutics, Inc. | Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5→16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high. | Closed | +13.2% |